Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Borras JM, Lievens Y, Barton M, et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol. 2016;119(1):5–11. doi:10.1016/j.radonc.2016.02.01626922487
   PubMedGoogle Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA: Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.2134927253694
   PubMed Web of Science ®Google Scholar
• Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–628. doi:10.1016/S1470-2045(18)30132-329650363
   PubMed Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–170. doi:10.1111/j.2042-7158.2012.01567.x23278683
   PubMed Web of Science ®Google Scholar
• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–1467. doi:10.1056/NEJMra110026527732808
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA: Cancer J Clin. 2016;66(4):309–325. doi:10.3322/caac.2134126919165
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975. doi:10.2147/IJN.S68861
   PubMed Web of Science ®Google Scholar
• Jiang L, Li L, He X, et al. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials. 2015;52:126–139. doi:10.1016/j.biomaterials.2015.02.00425818419
   PubMed Web of Science ®Google Scholar
• Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014;2(6):159–182. doi:10.1177/205101361454144025364509
   PubMedGoogle Scholar
• Barenholz Y. Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: from the bench to approved DOXIL In: Gregoriadis G, editor. Liposome Technol. Boca Raton: CRC Press; 2016:25–50.
   Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine. 2013;8(9):1509–1528. doi:10.2217/nnm.13.11823914966
   PubMed Web of Science ®Google Scholar
• Eloy JO, de Souza MC, Petrilli R, et al. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids and Surf B. 2014;123:345–363. doi:10.1016/j.colsurfb.2014.09.029
   PubMed Web of Science ®Google Scholar
• Liu HL, Fan CH, Ting CY, et al. Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. Theranostics. 2014;4(4):432. doi:10.7150/thno.807424578726
   PubMed Web of Science ®Google Scholar
• Christensen-Jeffries K, Browning RJ, Tang MX, et al. In vivo acoustic super-resolution and super-resolved velocity mapping using microbubbles. IEEE T Med Imaging. 2015;34(2):433–440. doi:10.1109/TMI.2014.2359650
   PubMed Web of Science ®Google Scholar
• Unger E, Porter T, Lindner J, Grayburn P. Cardiovascular drug delivery with ultrasound and microbubbles. Adv Drug Delivery Rev. 2014;72:110–126. doi:10.1016/j.addr.2014.01.012
   PubMed Web of Science ®Google Scholar
• Jeon M, Song W, Huynh E, et al. Methylene blue microbubbles as a model dual-modality contrast agent for ultrasound and activatable photoacoustic imaging. J Biomed Opt. 2014;19(1):016005. doi:10.1117/1.JBO.19.1.015008
   PubMed Web of Science ®Google Scholar
• Lohse D, Zhang X. Surface nanobubbles and nanodroplets. Rev Mod Phys. 2015;87(3):981. doi:10.1103/RevModPhys.87.981
   Web of Science ®Google Scholar
• Yu L, Yang JF, Lou XW. Formation of CoS2 nanobubble hollow prisms for highly reversible lithium storage. Angew Chem Int Ed. 2016;55(43):13422–13426. doi:10.1002/anie.201606776
   PubMed Web of Science ®Google Scholar
• Lohse D, Zhang X. Pinning and gas oversaturation imply stable single surface nanobubbles. Phys Rev E. 2015;91(3):031003. doi:10.1103/PhysRevE.91.031003
   Web of Science ®Google Scholar
• Zhu X, Verzicco R, Zhang X, Lohse D. Diffusive interaction of multiple surface nanobubbles: shrinkage, growth, and coarsening. Soft Matter. 2018;14(11):2006–2014. doi:10.1039/c7sm02523h29457812
   PubMedGoogle Scholar
• Teicher BA, Fricker P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–2931. doi:10.1158/1078-0432.CCR-09-232920484021
   PubMed Web of Science ®Google Scholar
• Xu C, Zhao H, Chen H, et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Dev Ther. 2015;9:4953.
   PubMed Web of Science ®Google Scholar
• Zhao H, Guo L, Zhao H, et al. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6(7):5022.25669980
   PubMedGoogle Scholar
• Scala S. Molecular pathways: targeting the CXCR4-CXCL12 axis-untapped potential in the tumor microenvironment. Clin Cancer Res. 2015;21(19):4278–4285. doi:10.1158/1078-0432.CCR-14-091426199389
   PubMed Web of Science ®Google Scholar
• Wester HJ, Keller U, Schottelius M, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5(6):618. doi:10.7150/thno.1125125825601
   PubMedGoogle Scholar
• Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7(4):477–487. doi:10.15252/emmm.20140469825736399
   PubMed Web of Science ®Google Scholar
• Zhong Y, Meng F, Deng C, et al. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15(6):1955–1969. doi:10.1021/bm500300924798476
   PubMed Web of Science ®Google Scholar
• He W, Wang Q, Srinivasan B, et al. A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene. 2014;33(23):3004. doi:10.1038/onc.2013.25623831571
   PubMed Web of Science ®Google Scholar
• Martins I, Raza SQ, Voisin L, et al. Anticancer chemotherapy and radiotherapy trigger both non-cell-autonomous and cell-autonomous death. Cell Death Dis. 2018;9(7):716. doi:10.1038/s41419-018-1111-y29915308
   PubMedGoogle Scholar
• Jain A, Tiwari A, Verma A, et al. Ultrasound-based triggered drug delivery to tumors. Drug Delivery Transl Res. 2018;8(1):150–164. doi:10.1007/s13346-017-0448-6
   PubMed Web of Science ®Google Scholar
• Paefgen V, Doleschel D, Kiessling F. Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery. Front Pharmacol. 2015;6:197. doi:10.3389/fphar.2015.0019726441654
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Lin Q, Wong HL, et al. Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery. J Controlled Release. 2016;224:112–125. doi:10.1016/j.jconrel.2016.01.015
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang J, Tian Y, et al. Targeted delivery of reduced graphene oxide nanosheets using multifunctional ultrasound nanobubbles for visualization and enhanced photothermal therapy. Int J Nanomed. 2018;13:7859. doi:10.2147/IJN
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637–1646. doi:10.1182/blood-2013-09-52580824366360
   PubMed Web of Science ®Google Scholar
• Qin L, Kufareva I, Holden LG, et al. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science. 2015;347(6226):1117–1122. doi:10.1126/science.126106425612609
   PubMedGoogle Scholar
• Guo F, Wang Y, Liu J, et al. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35(7):816. doi:10.1038/onc.2015.13925961926
   PubMed Web of Science ®Google Scholar
• Kinouchi M, Uchida D, Kuribayashi N, et al. AMD070, a novel orally bioavailable CXCR4 inhibitor, inhibits the metastases of oral cancer via SDF-1/CXCR4 system[abstract]. Am Assoc Cancer Res. 2016;76(suppl14):4117.
   Google Scholar
• Kuribayashi N, Uchida D, Kinouchi M, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells[abstract]. Am Assoc Cancer Res. 2018;78(suppl13):4191.
   Google Scholar
• Morimoto M, Matsuo Y, Koide S, et al. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. BMC Cancer. 2016;16(1):305. doi:10.1186/s12885-016-2340-z27175473
   PubMedGoogle Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235. doi:10.1016/S1470-2045(14)70420-625240821
   PubMed Web of Science ®Google Scholar
• Stathis A, Hess D, von Moos R, et al. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2017;35(6):766–772. doi:10.1007/s10637-017-0454-z28317088
   PubMedGoogle Scholar
• Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi:10.1016/S0140-6736(18)31257-129880231
   PubMed Web of Science ®Google Scholar